| Budget Amount *help |
¥18,720,000 (Direct Cost: ¥14,400,000、Indirect Cost: ¥4,320,000)
Fiscal Year 2014: ¥3,510,000 (Direct Cost: ¥2,700,000、Indirect Cost: ¥810,000)
Fiscal Year 2013: ¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2012: ¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2011: ¥6,370,000 (Direct Cost: ¥4,900,000、Indirect Cost: ¥1,470,000)
|
|---|
| Outline of Final Research Achievements |
Using two mouse model of retinal edema, i.e., receptor-activity-modifying protein (RAMP)-2 knockout mouse and kimba mouse which overexpresses vascular endothleial growth factor (VEGF) in the retina, we pursued the possibility for experimental treatment for macular edema. We investigated the effect of intraocular injection ofβ-catenin、PPARγ-ligand、apelin on retinal vascular leakage, but none of them exhibited prominent reducing effect of fluorescein dye leakage in flurorescein angiography. Then we investigated the effect of intravitreal and systemic injection of adrenomedullin on the hyperpermeability of retinal vessels in kimba mice. Adrenomedullin reduced fluorescein dye leakage from retinal vessels in kimba mice suggesting its therapeutic effect on retinal edema, in which VEGF plays a causative role. Since half-life of adrenomedullin is short, we consider that we have to synthesize a fusion protein of adrenomedullin and Fc portion of IgG to make its effect long lasting.
|
